Einträge von Krex, Dietmar auf dem Publikationsserver

Hertler, Caroline, Felsberg, Jörg, Gramatzki, Dorothee , Le Rhun, Emilie, Clarke, Jennifer , Soffietti, Riccardo, Wick, Wolfgang , Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F., Reijneveld, Jaap, Schnell, Oliver, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A., van den Bent, Martin , Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F., Phillips, Samuel, Rudà, Roberta, Wick, Antje , Tabouret, Emeline, Meyronet, David, Maurage, Claude-Alain, Rushing, Elisabeth, Rapkins, Robert, Bumes, Elisabeth, Hegi, Monika, Weyerbrock, Astrid, Aregawi, Dawit, Gonzalez-Gomez, Christian, Pellerino, Alessia , Klein, Martin, Preusser, Matthias , Bendszus, Martin, Golfinopoulos, Vassilis, von Deimling, Andreas, Gorlia, Thierry, Wen, Patrick Y., Reifenberger, Guido und Weller, Michael (2023) Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). European Journal of Cancer 189, S. 112913. Volltext nicht vorhanden.

Zeyen, Thomas, Paech, Daniel, Weller, Johannes, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Steinbach, Joachim Peter, Hau, Peter, Schlegel, Uwe, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, Galldiks, Norbert, Stummer, Walter, Hattingen, Elke, Glas, Martin, Radbruch, Alexander, Herrlinger, Ulrich und Schaub, Christina (2023) Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. Journal of Neuro-Oncology 164 (3), S. 607-616. Volltext nicht vorhanden.

Weller, Johannes , Schäfer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael , Hau, Peter , Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Güresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich und Schneider, Matthias (2022) Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. Journal of Neuro-Oncology 159 (1), S. 95-101.

Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael , Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Güresir, Erdem, Schmid, Matthias , Schuss, Patrick , Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank , Herrlinger, Ulrich und Schneider, Matthias (2022) Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial. Trials 23 (1). Volltext nicht vorhanden.

Tzaridis, Theophilos , Schäfer, Niklas, Weller, Johannes, Steinbach, Joachim‐Peter, Schlegel, Uwe, Seidel, Sabine, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Tonn, Jörg‐Christian, Grauer, Oliver, Kebir, Sied, Schneider, Matthias, Schaub, Christina, Vatter, Hartmut, Coch, Christoph, Glas, Martin, Fimmers, Rolf, Pietsch, Torsten, Reifenberger, Guido, Herrlinger, Ulrich und Felsberg, Jörg (2021) MGMT promoter methylation analysis for allocating combined CCNU / TMZ chemotherapy: Lessons learned from the CeTeG / NOA ‐09 trial. International Journal of Cancer 148 (7), S. 1695-1707. Volltext nicht vorhanden.

Gutzmer, Ralf, Vordermark, Dirk, Hassel, Jessica C., Krex, Dietmar, Wendl, Christina, Schadendorf, Dirk, Sickmann, Thomas, Rieken, Stefan, Pukrop, Tobias, Höller, Christoph, Eigentler, Thomas K. und Meier, Friedegund (2020) Melanoma brain metastases – Interdisciplinary management recommendations 2020. Cancer Treatment Reviews 89, S. 102083. Volltext nicht vorhanden.

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert , Weller, Johannes , Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh , Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin und Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Journal of Neuro-Oncology 144 (3), S. 501-509. Volltext nicht vorhanden.

Weller, Johannes , Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert , Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich und Schäfer, Niklas (2019) Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 20 (10), S. 1444-1453. Volltext nicht vorhanden.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.

Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter , Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich und Glas, Martin (2018) Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. Journal of Cancer Research and Clinical Oncology 144 (8), S. 1581-1589. Volltext nicht vorhanden.

Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter , Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin und Herrlinger, Ulrich (2017) Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology 20 (7), S. 975-985. Volltext nicht vorhanden.

Herrlinger, Ulrich, Schäfer, Niklas, Steinbach, Joachim P. , Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W. , Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Hänel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Rüdiger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tüttenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter und Glas, Martin (2016) Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of Clinical Oncology 34 (14), S. 1611-1619. Volltext nicht vorhanden.

Eigentler, Thomas K. , Figl, Adina, Krex, Dietmar, Mohr, Peter, Mauch, Cornelia, Rass, Knut, Bostroem, Azize, Heese, Oliver, Koelbl, Oliver, Garbe, Claus und Schadendorf, Dirk (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117 (8), S. 1697-1703. Volltext nicht vorhanden.